0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Highlights

          No specific treatment against SARS-CoV-2 is available after 6 months of COVID-19 worldwide outbreak

          Antivirals could decrease the viral load and reduce direct and indirect damages of SARSCoV-2 infection

          Ritonavir-bosted lopinavir is effective against SARS-CoV-2 in vitro

          Sequential virological and pharmacological monitoring helped to understand the efficacy of ritonavir-boosted lopinavir in a SARS-CoV-2 infected patient

          Ritonavir-boosted lopinavir could be proposed as early treatment for SARS-CoV-2 infection

          Related collections

          Most cited references 4

          • Record: found
          • Abstract: not found
          • Article: not found

          Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China, January to February 2020

           Y. Xing,  P Mo,  Y Xiao (2020)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs

            COVID-19 is an emerging infectious disease and was recently declared as a pandemic by WHO. Currently, there is no vaccine or therapeutic available for this disease. Drug repositioning represents the only feasible option to address this global challenge and a panel of fifty FDA-approved drugs that have been pre-selected by an assay of SARS-CoV was screened to identify potential antiviral drug candidates against SARS-CoV-2 infection. We found a total of 24 drugs which exhibited antiviral efficacy (0.1 μM < IC50 < 10 μM) against SARS-CoV-2. In particular, two FDA-approved drugs – niclosamide and ciclesonide – were notable in some respects. These drugs will be tested in an appropriate animal model for their antiviral activities. In near future, these already FDA-approved drugs could be further developed following clinical trials in order to provide additional therapeutic options for patients with COVID-19.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              The first locally acquired novel case of 2019-nCoV infection in a healthcare worker in the Paris area

                Bookmark

                Author and article information

                Contributors
                Journal
                J Infect
                J. Infect
                The Journal of Infection
                The British Infection Association. Published by Elsevier Ltd.
                0163-4453
                1532-2742
                27 May 2020
                27 May 2020
                Affiliations
                [a ] Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique , and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Maladies Infectieuses et Tropicales, Paris , France
                [b ] Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique , and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Virologie, Paris , France
                [c ] Assistance Publique - Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Laboratoire de Pharmacologie-Toxicologie , DMU Biologie et Génomique Médicale (BioGeM), IAME INSERM UMR-S 1137, Paris , France
                [d ] Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Virologie, Paris , France
                [e ] Assistance Publique - Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Laboratoire de Pharmacologie-Toxicologie , DMU Biologie et Génomique Médicale (BioGeM), INSERM UMR-S 1144, Paris , France
                [f ] Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Maladies Infectieuses et Tropicales, Paris , France
                [g ] Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique , and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Virologie, Paris , France
                [h ] Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique , and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Virologie, Paris , France
                [i ] Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique , and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Maladies Infectieuses et Tropicales, Paris , France
                [j ] Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique , and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Maladies Infectieuses et Tropicales, Paris , France
                [k ]Sorbonne Université, INSERM 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Virologie, Paris, France
                Author notes
                [* ]Corresponding author: Elise Klement-Frutos, Hôpitaux Universitaires Pitié-Salpêtrière - Charles Foix, Service de Maladies Infectieuses et Tropicales, 47-83 Bd de l'Hôpital, 75013, Paris, France, Phone +33 1 42 16 03 97 elisemarie.klement@ 123456aphp.fr
                [1]

                Both authors contributed equally to the present work.

                Article
                S0163-4453(20)30318-2
                10.1016/j.jinf.2020.05.039
                7251410
                © 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                Categories
                Article

                Comments

                Comment on this article